Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
BörsenkürzelBHC
Name des UnternehmensBausch Health Companies Inc
IPO-datumSep 20, 1994
CEOMr. Thomas J. Appio
Anzahl der mitarbeiter20700
WertpapierartOrdinary Share
GeschäftsjahresendeSep 20
Addresse2150 St. Elzear Blvd. West
StadtLAVAL
BörseThe Toronto Stock Exchange
LandCanada
PostleitzahlH7L 4A8
Telefon18003611448
Websitehttps://www.bauschhealth.com/
BörsenkürzelBHC
IPO-datumSep 20, 1994
CEOMr. Thomas J. Appio
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten